Side-by-side comparison of AI visibility scores, market position, and capabilities
Precision fermentation biotech producing animal-free growth factors for cultivated meat and cell therapy; Drosophila expression system enabling lower-cost recombinant protein production.
Future Fields is a precision fermentation biotechnology company producing recombinant growth factors and proteins for the cultivated meat and cell therapy industries — using Drosophila (fruit fly) expression system to manufacture animal-free, scalable alternatives to animal serum-derived growth factors that are a major cost driver in cell-based biotech production. Founded in 2019 by Matthew Anderson-Baron and Jalene Anderson-Baron in Edmonton, Canada, Future Fields has raised approximately $11 million and targets the cultivated meat industry and cell therapy manufacturers who need cost-effective, animal-free growth factor supply.\n\nFuture Fields' EntoEngine platform uses genetically modified Drosophila to produce recombinant proteins (growth factors like FGF, EGF, IGF, TGF) at lower cost than mammalian cell expression systems — the Drosophila system is faster to scale, has lower infrastructure requirements, and produces proteins at commercially viable price points. For the cultivated meat industry, growth factors represent one of the largest cost components in cell culture media, and animal-free sources are preferred both for cost and for meeting "animal-free" product claims.\n\nIn 2025, Future Fields competes with Mycenax Biotech, Ajinomoto, and conventional growth factor suppliers for the cell culture media market. The cultivated meat industry has faced headwinds as commercialization timelines have extended and regulatory approvals have been slower than anticipated, but cell therapy (CAR-T, stem cell therapy, gene therapy) manufacturing represents a large adjacent market for Future Fields' growth factors. The 2025 strategy focuses on growing revenue from cell therapy manufacturers who need GMP-grade recombinant proteins, continuing to reduce production costs, and positioning as the commercial-scale alternative to FBS-derived growth factors.
$500M Series D at $11B valuation (Feb 2026) — largest voice AI funding round ever. $330M ARR; 1M+ developers using the API. Enterprise customers: Deutsche Telekom, Revolut, Meta, Salesforce. Voices in 32 languages; real-time cloning from 1 second of audio.
ElevenLabs was founded in 2022 by Piotr Dabkowski and Mati Staniszewski, two former Google and Palantir engineers who set out to break the language barrier using AI voice technology. The company specializes in AI-powered voice synthesis, cloning, and dubbing, enabling developers and enterprises to generate human-quality speech in over 30 languages. Its core technology combines deep learning models trained on massive speech datasets to produce natural-sounding voices indistinguishable from real humans.\n\nElevenLabs offers a suite of products including its flagship text-to-speech API, voice cloning tools, and an AI dubbing platform that localizes video content while preserving the speaker's original voice. Its products target a broad audience—from indie developers building audio apps to large enterprises deploying voice interfaces at scale. Key differentiators include ultra-low latency streaming synthesis, fine-grained voice customization, and a growing library of pre-built AI voices across accents and styles.\n\nElevenLabs has grown rapidly, surpassing $330M in annualized revenue and serving over 1 million developers. Enterprise clients include Deutsche Telekom, Spotify, and leading media companies. In February 2026, the company closed a $500M Series D at an $11B valuation, cementing its position as the market leader in AI voice. Its APIs power podcasts, audiobooks, video games, and customer service bots worldwide, making ElevenLabs the default infrastructure layer for AI-generated audio.
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.